Insulin analogue or its pharmaceutically acceptable salt, pharmaceutical composition with prolonged therapeutic effect, use of the insulin analogue, dosage method and method of treatment of diabetes

The invention relates to an insulin analogue or its pharmaceutically acceptable salt, pharmaceutical composition with prolonged therapeutic effect, application of the insulin analogue, dosage method and method of treatment of diabetes. In more detail, the solution pertains to compounds being stable...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Hauptverfasser: Płucienniczak Andrzej, Wojtowicz-Krawiec Anna, Zieliński Marcin, Borowicz Piotr, Płucienniczak Graźyna, Pawlukowiec Tomasz, Pawłowska Monika, Antosik Jarosław, Kęsik-Brodacka Malgorzata, Stępniewski Jacek, Łukasiewicz Natalia, Bernat Justyna, Pstrzoch Jacek, Kurzynoga Dariusz, Sokołowska Iwona, Głąbski Tadeusz, Bogiel Monika, Stadnik Dorota, Cecuda-Adamczewska Violetta, Mikołajczyk Jerzy, Mikiewicz-Syguła Diana, Tejchman-Małecka Boźena
Format: Patent
Sprache:eng
Schlagworte:
Online-Zugang:Volltext bestellen
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:The invention relates to an insulin analogue or its pharmaceutically acceptable salt, pharmaceutical composition with prolonged therapeutic effect, application of the insulin analogue, dosage method and method of treatment of diabetes. In more detail, the solution pertains to compounds being stable insulin analogues which are pharmaceutically active and characterized by a prolonged, flat, truly peakless course of glucose concentration vs. time during repeated administration and which do not show strong 24 hours fluctuations of glucose concentration, or the so-called "sawteeth effect", during this time. Results of studies of compounds included in the scope of this application indicate an improvement in the effects of diabetes treatment by avoiding the hitherto occurring adverse influence of changes in glucose concentration throughout the entire day on a patient's organism, e.g. night hypoglycaemias, because truly peakless, long-acting insulin should reproduce correct endogenous insulin secretion in the therapy, as is provided by a healthy pancreas at a proper and constant 24 hours level.